Day: December 5, 2024

TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) — Montauk Metals Inc. (TSX-V: MTK) (the “Company” or “Montauk”) announces that the Company received USD$504,000 from the Republic of Colombia as a costs award in conjunction with International Centre for Settlement of Investment Disputes (“ICSID”) Arbitral Tribunal (the “Tribunal”) ruling, as more fully detailed in the Company’s press release dated June 10, 2024. The Company further announces that the Company repaid USD$235,135, inclusive of USD$35,135 of accrued interest, to Omni Bridgeway (Fund 5) Canada Investments Ltd. (“Omni”), constituting the entirety of the funds owed by the Company to Omni pursuant to the loan and option agreement between the parties, as more fully detailed in the Company’s press release dated December 28, 2023. RISK DISCLOSURE STATEMENT: At the present time, the...

Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. (“J-Will”), through which JKI will acquire Teva-Takeda The agreement is aligned with Teva’s Pivot to Growth strategy to focus its business The expected divestment of Teva-Takeda, Teva’s business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese marketTEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) — Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva...

LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company’s COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada. The highlights of the presentation, titled, “COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results” (Abstract # 302), include:Study Update: As of November 15, 2024, a total of 217 participants have been enrolled and 183 participants were assigned to either MN-166 or placebo group. Pre-defined...

Focused on efficiency, processing revenue growth & debt reduction NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATES CALGARY, Alberta, Dec. 05, 2024 (GLOBE NEWSWIRE) — Pieridae Energy Limited (“Pieridae” or the “Company”) (TSX: PEA) is pleased to provide 2025 guidance including scope of the 2025 capital program along with production and Net Operating Income1 (“NOI”) projections.2025 Guidance Estimates Initial Guidance (Dec-24)Low HighProduction (boe/d) 23,000 25,000NOI ($M) (1)(2)(3) $75,000 $95,000Operating Netback ($/boe) (1)(2)(3) $9.00 $11.00Capital Expenditures ($M) $25,000 $30,000(1) Refer to the “non-GAAP measures” section of the Company’s latest MD&A(2) Assumes average 2025 AECO price of $2.34/GJ and average 2025 WTI price of USD$68.25/bbl(3) Accounts...

CALGARY, Alberta, Dec. 05, 2024 (GLOBE NEWSWIRE) — Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) is pleased to announce its 2025 budget with capital projects that will balance cash flow growth while continuing to deliver a durable return of capital framework that will direct 100% of Free Cash Flow to share buybacks in 2025. Corporate Consolidated Strategy and OutlookValue Creation Strategy. Athabasca provides a differentiated liquids-weighted growth platform through its low-decline, long-life Thermal Oil assets. Athabasca’s subsidiary company, Duvernay Energy Corporation (“DEC”), is designed to enhance value for Athabasca’s shareholders by providing a clear path for self-funded production and cash flow growth in the Kaybob Duvernay resource play. Athabasca (Thermal Oil) and DEC have independent strategies...